• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Clin Pract . Clinical, SinoNasal, and Long-Term Smell and Taste Outcomes in Mildly Symptomatic COVID-19 Patients

tetano

Editor, Senior Moderator
Int J Clin Pract


. 2021 Apr 22;e14260.
doi: 10.1111/ijcp.14260. Online ahead of print.
Clinical, SinoNasal, and Long-Term Smell and Taste Outcomes in Mildly Symptomatic COVID-19 Patients


Amjed Tarifi[SUP] 1 [/SUP], Amjad A Al Shdaifat[SUP] 2 [/SUP], Abdel-Ellah M Al-Shudifat[SUP] 2 [/SUP], Mohammed Azab[SUP] 3 [/SUP], Ja'far Ismail[SUP] 4 [/SUP], Rand Bashir[SUP] 5 [/SUP], Aous Amro[SUP] 6 [/SUP], Ahmad Altarifi[SUP] 7 [/SUP], Yousef Khader[SUP] 8 [/SUP]



Affiliations

Abstract

Introduction: Coronavirus 2019 disease (COVID-19) has variable clinical, sinonasal, and smell/taste outcomes.
Methods: Observational study was conducted at a tertiary hospital in Amman, Jordan. Demographic data, clinical presentation, and smoking status were collected. Sinonasal symptoms, using Sino-Nasal Outcome Test (SNOT-22) Questionnaire, were evaluated. Smell/taste dysfunction was followed for three months.
Results: Ninety-Seven patients had satisfactory responses. Eighty-six patients were symptomatic (41 at presentation, and 45 during admission). Among those patients, 59.3% had cough, 52.3% sore throat, and 48.8% fever. The most common initial symptom was sore throat. Shortness of breath and smell/taste dysfunction were significantly higher in females. Surprisingly, shortness of breath was more common in non-smokers. Smell/taste dysfunction affected 25.6 % of patients, but was the first symptom in only one patient. Fourteen out of 22 symptoms in SNOT-22 had significant increase. The overall average of symptoms scores increased from 0.472 to 1.034, with smell/taste dysfunction to have the most increment. The latter symptom recovered completely in 81% and dysgeusia developed in 9.5% at three months, and itrecovered completely in all patients at six months.
Conclusion: Although COVID-19 may produce severe lower airways disease, it has modest effect on nose and paranasal sinuses. Moreover, smell/taste dysfunction is a prominent symptom, but it usually recovers dramatically.

Keywords: COVID-19; dysgeusia; olfaction; sinonasal; smell; taste.
 
Back
Top Bottom